Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-21

Clinical Trial Update: Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).

View source ↗

Summary

Clinical trial update for a post-marketing commitment study of sunitinib malate in gastrointestinal stromal tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sunitinib malate (sunitinib malate)

Snippet

Sponsor: Pfizer | Conditions: Gastrointestinal Stromal Tumors | Status: COMPLETED | Results posted: 2016-10-21